John M Lewis, MD
Ophthalmology · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Offices
- 2
Offices
2 locations · Permanente Medical Group Inc · 10,928 clinicians in this group
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lewis’s office at (408) 851-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
California Medical Board record
Licence G77840 · Current
Licensed to practise in California · since 1993 · expires 2027-10-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$5,961
Medicare paid this office $5,961 for 13 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
13 Original Medicare patients in 2024. Average age 67 · Health risk score 2.08. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.
The office billed $24,868, Medicare allowed $8,931 and paid $5,961; for 33 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 13 | 33 | 67 | 2.08 | $24,868 | $5,961 |
| 2021 | 14 | 118 | 62 | 2.99 | $65,239 | $17,869 |
| 2020 | 12 | 100 | 63 | 5.13 | $51,491 | $14,350 |
| 2019 | 15 | 118 | 66 | 3.35 | $43,491 | $13,965 |
| 2018 | 17 | 61 | 66 | 5.48 | $27,511 | $7,173 |
| 2017 | 17 | 41 | 64 | 2.89 | $21,531 | $3,309 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2021: 1 service
| Established patient problem focused exam of visual system | 11 | $2,176 | $75 |
2019: 1 service
| Established patient problem focused exam of visual system | 13 | $2,121 | $73 |
2018: 1 service
| Established patient problem focused exam of visual system | 13 | $1,656 | $75 |
Medicaid work
$49,969 in 2024
Medicaid paid $49,969 for 476 billed services this clinician did in 2024, up to 24 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 85 | $21,750 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 218 | $20,104 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 160 | $7,519 |
| Compounded drug, not otherwise classified | 13 | $596 |
| 2024 | 476 | 4 | 24 | $49,969 |
| 2023 | 291 | 3 | 22 | $675 |
| 2022 | 90 | 2 | 13 | $0 |
| 2021 | 45 | 2 | 16 | $39 |
| 2020 | 12 | 1 | 12 | $0 |
See the largest Medicaid services in earlier years
2023
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 137 | $505 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 116 | $170 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 38 | $0 |
2022
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 64 | $0 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 26 | $0 |
2021
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 32 | $39 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 13 | $0 |
2020
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 12 | $0 |
Drugs they prescribed that Part D paid
$14,265
Pharmacies billed $14,265 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
332 generic and 134 brand-name prescriptions · $14,265 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 129 | $6,936 | $54 |
| Dorzolamide-Timolol | 91 | $1,708 | $19 |
| Polymyxin B Sul-Trimethoprim | 59 | $725 | $12 |
| Latanoprost | 49 | $621 | $13 |
| Diclofenac | 43 | $579 | $13 |
See all 6 drugs
| Prednisolone Acetate | 129 | $6,936 | $54 |
| Dorzolamide-Timolol | 91 | $1,708 | $19 |
| Polymyxin B Sul-Trimethoprim | 59 | $725 | $12 |
| Latanoprost | 49 | $621 | $13 |
| Diclofenac | 43 | $579 | $13 |
| Brimonidine | 18 | $230 | $13 |
Year by year
| 2024 | 466 | 171 | None | 29% | $14,265 |
| 2023 | 488 | 164 | None | None | $15,371 |
| 2022 | 494 | 166 | None | 36% | $14,796 |
| 2021 | 454 | 134 | None | 34% | $21,152 |
| 2020 | 358 | 116 | 0% (0) | 32% | $15,337 |
| 2019 | 364 | 127 | None | 32% | $19,562 |
| 2018 | 419 | 147 | 3% (12) | 31% | $20,595 |
| 2017 | 396 | 142 | None | 38% | $18,098 |
| 2016 | 460 | 143 | 4% (20) | 30% | $18,828 |
| 2015 | 389 | 139 | None | 30% | $15,688 |
| 2014 | 387 | 125 | 3% (12) | 34% | $20,224 |
| 2013 | 345 | 108 | 5% (18) | 33% | $14,570 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Prednisolone Acetate | 150 | $8,402 | $56 |
| Dorzolamide-Timolol | 67 | $1,266 | $19 |
| Polymyxin B Sul-Trimethoprim | 58 | $654 | $11 |
| Latanoprost | 38 | $463 | $12 |
| Ofloxacin | 25 | $389 | $16 |
| Diclofenac | 27 | $340 | $13 |
| Ketorolac Tromethamine | 20 | $297 | $15 |
| Brimonidine | 26 | $290 | $11 |
2022: 7 drugs
| Prednisolone Acetate | 158 | $7,888 | $50 |
| Dorzolamide-Timolol | 75 | $1,371 | $18 |
| Latanoprost | 49 | $766 | $16 |
| Polymyxin B Sul-Trimethoprim | 61 | $686 | $11 |
| Diclofenac | 37 | $465 | $13 |
| Brimonidine | 23 | $264 | $11 |
| Ofloxacin | 23 | $252 | $11 |
2021: 6 drugs
| Prednisolone Acetate | 138 | $10,797 | $78 |
| Dorzolamide-Timolol | 62 | $1,410 | $23 |
| Latanoprost | 59 | $904 | $15 |
| Polymyxin B Sul-Trimethoprim | 69 | $793 | $11 |
| Diclofenac | 34 | $500 | $15 |
| Brimonidine | 19 | $283 | $15 |
2020: 6 drugs
| Prednisolone Acetate | 102 | $5,130 | $50 |
| Dorzolamide-Timolol | 76 | $1,960 | $26 |
| Latanoprost | 52 | $977 | $19 |
| Diclofenac | 31 | $604 | $19 |
| Polymyxin B Sul-Trimethoprim | 31 | $370 | $12 |
| Brimonidine | 14 | $218 | $16 |
2019: 6 drugs
| Prednisolone Acetate | 94 | $5,360 | $57 |
| Dorzolamide-Timolol | 58 | $1,725 | $30 |
| Latanoprost | 61 | $1,014 | $17 |
| Diclofenac | 26 | $579 | $22 |
| Polymyxin B Sul-Trimethoprim | 42 | $501 | $12 |
| Brimonidine | 12 | $181 | $15 |
2018: 7 drugs
| Prednisolone Acetate | 120 | $9,247 | $77 |
| Dorzolamide-Timolol | 65 | $1,110 | $17 |
| Latanoprost | 41 | $876 | $21 |
| Polymyxin B Sul-Trimethoprim | 69 | $817 | $12 |
| Diclofenac | 37 | $643 | $17 |
| Brimonidine | 17 | $285 | $17 |
| Erythromycin | 12 | $219 | $18 |
2017: 8 drugs
| Prednisolone Acetate | 127 | $9,432 | $74 |
| Dorzolamide-Timolol | 52 | $920 | $18 |
| Latanoprost | 36 | $761 | $21 |
| Polymyxin B Sul-Trimethoprim | 61 | $603 | $10 |
| Diclofenac | 30 | $532 | $18 |
| Neomycin-Polymyxin-Dexameth | 18 | $396 | $22 |
| Brimonidine | 13 | $246 | $19 |
| Timolol Maleate | 12 | $167 | $14 |
2016: 11 drugs
| Prednisolone Acetate | 114 | $8,711 | $76 |
| Zymaxid | 14 | $1,260 | $90 |
| Dorzolamide-Timolol | 62 | $1,065 | $17 |
| Latanoprost | 43 | $866 | $20 |
| Diclofenac | 39 | $845 | $22 |
| Brimonidine | 26 | $613 | $24 |
| Ofloxacin | 40 | $546 | $14 |
| Neomycin-Polymyxin-Dexameth | 22 | $385 | $18 |
| Acetaminophen-Codeine | 19 | $211 | $11 |
| Timolol Maleate | 13 | $187 | $14 |
| Polymyxin B Sul-Trimethoprim | 18 | $168 | $9 |
2015: 8 drugs
| Prednisolone Acetate | 106 | $8,082 | $76 |
| Diclofenac | 31 | $846 | $27 |
| Dorzolamide-Timolol | 48 | $806 | $17 |
| Brimonidine | 32 | $637 | $20 |
| Latanoprost | 29 | $606 | $21 |
| Ofloxacin | 60 | $501 | $8 |
| Dorzolamide | 14 | $318 | $23 |
| Neomycin-Polymyxin-Dexameth | 12 | $285 | $24 |
2014: 9 drugs
| Prednisolone Acetate | 103 | $8,569 | $83 |
| Diclofenac | 47 | $974 | $21 |
| Latanoprost | 28 | $601 | $21 |
| Dorzolamide-Timolol | 30 | $580 | $19 |
| Ofloxacin | 51 | $436 | $9 |
| Neomycin-Polymyxin-Dexameth | 18 | $435 | $24 |
| Erythromycin | 15 | $297 | $20 |
| Timolol Maleate | 14 | $278 | $20 |
| Brimonidine | 15 | $226 | $15 |
2013: 11 drugs
| Lumigan | 12 | $3,172 | $264 |
| Prednisolone Acetate | 64 | $2,176 | $34 |
| Dorzolamide-Timolol | 41 | $1,447 | $35 |
| Neomycin-Polymyxin-Dexameth | 29 | $875 | $30 |
| Diclofenac | 35 | $781 | $22 |
| Latanoprost | 28 | $499 | $18 |
| Ofloxacin | 36 | $310 | $9 |
| Timolol Maleate | 14 | $295 | $21 |
| Brimonidine | 17 | $236 | $14 |
| Hydrocodone-Acetaminophen | 15 | $150 | $10 |
| Levobunolol | 11 | $122 | $11 |
Money from drug and device companies
$94 in 2025
| 2025 | 1 | 1 | None | $94 |
| 2023 | 1 | 1 | None | $60 |
| 2022 | 1 | 2 | None | $167 |
| 2019 | 1 | 1 | None | $127 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Izervay | $94 | 1 payment
|
See the published payment
| Astellas Pharma US | Meals · 2025-08-02 | Izervay | $94 |
See earlier years (2023, 2022, 2019)
2023: $60
| Mallinckrodt Hospital Products | Acthar | $60 | 1 payment
|
2022: $167
| Alcon Vision | Ngenuity | $167 | 2 payments
|
2019: $127
| Allergan | Ozurdex | $127 | 1 payment
|
Professional record
- NPI
- 1225115181
- Licence
- CA G77840California G77840: Current · expires 2027-10-31
- Trained
- University of California, Davis School of Medicine, 1991
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G778400
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1800 Harrison St Fl 7, Oakland, CA, 94612
- NPI first listed
- 2006-10-31
- NPI last updated
- 2021-12-13
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.